Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou
Xinyuan Zhenghe (Hangzhou) Private Equity Fund Management Co., Ltd., Sirnaomics, and the Fuyang Economic and...
Deals
HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones
HBM Holdings Limited (HKG: 2142) announced it has entered into a long-term global strategic collaboration...
Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody
Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive...
Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline
Byterna Therapeutics completed its angel plus round financing, exclusively invested by Efung Capital. Proceeds will...
Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving...
Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones
Jiangsu Hansoh Pharmaceutical Co. Ltd. (HKG: 3692) entered into an exclusive license, collaboration, and distribution...
Fangzhou and Huilun Partner on AI-Driven Chronic Disease Management Platform
Guangzhou-based smart healthcare service platform Fangzhou Inc. (HKG: 6086) and Shanghai Huilun Pharmaceutical Co., Ltd....
Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
Saizeng Medical Technology Co. Ltd, a subsidiary of Changchun High‑Tech Industry (Group) Co., Ltd. (SHE:...
uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials
uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next‑generation...
Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option
Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop...
Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non‑exclusive agreements with Pfizer Inc. (NYSE: PFE) to...
Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio
Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) announced a definitive agreement to acquire Arthrosi Therapeutics,...
Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing
Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...
Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. released its prospectus for a Hong Kong Stock Exchange listing...
Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
Hasten Biopharmaceutical Co., Ltd. and Everest Medicines Limited (HKG: 1952) announced two strategic agreements: a...
InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a...
Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
Brii Biosciences Limited (HKG: 2137) announced a collaboration with OpenBench to leverage its structure‑driven Artificial...
GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) has initiated a breakup with Ideaya Biosciences (NASDAQ:...
B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering...